Single-cell analysis is to change the understanding of the disease. There is a growing realization that cell populations are more diverse and complex than human thinking. Advances in single-cell genomics, transcriptomics, and proteomics are also transforming clinical research, diagnosis, and treatment of various diseases. The single-cell multi-omics technology refers to multiple types of molecules from the individual cells, which is studied to understand the more biological insight than deducing from analyzing each molecular layer from separate cells.
The global single-cell multi-omics market to bolster the growth at tremendous CAGR in the forecast period from 2020-2027. Due to the rising adoption of personalized medicine, the use of non-invasive instruments, changing individual lifestyles, advancement in single-cell technology have fueled the market demand for the global single-cell multi-omics market.
Single-cell sequencing refers to the technology of obtaining corresponding data and performing information analysis by sequencing a single cell at the genome, transcriptome, and epigenome levels. Single-cell sequencing can solve the problem of cell heterogeneity that cannot be solved by sequencing tissue samples, and provides a new method for analyzing the behavior, mechanism, and relationship between the single-cell and the body.
The advantage of this type of method is that it can obtain higher coverage and accuracy information from a single cell, which is suitable for a high-quality analysis of precious samples that are difficult to obtain.
Moreover, the rising number of chronic diseases has increased the market demand for single-cell multi-omics technology, which helps in finding the cure for diseases like cancer. Also, the rising personalized medicine market due to growing infections, have fueled the global market for a single cell multi-omics market.
Additionally, growing biotechnology and the pharmaceutical industry have propelled the demand for non-invasive instruments, full applications for single-cell multi-omics technology, and conventional labs are bolstering the future clinical market.
The rising chronic diseases like cancer and infectious diseases caused due to viruses have emerged the market growth for the global single-cell multi-omics market. The advantage of single-cell technology is that additional layers of data associated with omics will add information that is critical to obtaining a full understanding of the biology of cellular heterogeneity.
Based on high-tech technology, scientists have started using tools that allow the use of single-cell sequencing for the exploration of cellular heterogeneity. It helps in improving personalized medicines and a rise in the development of the pharmaceutical industry and the health of the patient.
Based on the product, the global single-cell multi-omics market segmented into Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics. Single-cell transcriptomics has captured the largest segment in the global single-cell multi-omics market. Transcriptome broadly refers to the collection of all transcription products in a cell under a particular physiological condition, including messenger RNA, ribosomal RNA, transport RNA, and non-coding RNA; narrowly refers to the collection of all mRNAs. Transcriptome sequencing can detect the overall transcription activity of any species without designing probes for known sequences in advance. It provides accurate digital signals, higher detection throughput, and a more comprehensive range detection used for an in-depth study of the complexity of the transcriptome.
Based on the Application, the global single-cell multi-omics market classified into Oncology, Cell Biology, Neurology, Immunology, Others. Oncology holds the largest market share in the global single-cell multi-omics market. Tumors and immunity are the most complex physiological environment in the body. Increasing evidence shows that tumorigenesis and development are strictly related to the dysfunction of the immune system. In the tumor environment, no matter tumor cells or immune cells, there are a large number of specific mutation sites or surface markers. Extensive heterogeneity of cells in the body, the timeliness of the expression of related factors, and the dynamic process of changes all seriously affect the effectiveness of the treatment plan. Therefore, oncology has fueled the market demand for the global single-cell multi-omics market in the forecast period from 2020-2027.
Based on geography, the global single-cell multi-omics market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The Asia Pacific will be expecting to witness the highest growth during the forecast period from 2020-2027. The number of cancer cases is increasing, growing patients, outsourcing of the drug discovery is rising, and investment in R&D for diagnostic labs, technology advancement is propelling the market demand. Moreover, North America is currently leading the market of the single-cell multi-omics market.
Companies such as 10x Genomics, Inc., MissionBio, 1CellBio, NanoString Technologies, Inc., Fluxion Biosciences, Fluidigm Corporation, Celsee, Inc., Bio-Rad Laboratories, Inc., BGI Genomics Co. Ltd., GE LifeSciences, Illumina, Inc., and Takara Bio, QIAGEN N.V., among others, are key players in the global single-cell multi-omics market.
By Disease Indication